ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last441 to 460 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke864 of 9,333

1,014 of 9,291

-1.7 points

-2.5 to -0.8

18,624NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

TICAGRELOR vs CLOPIDOGREL: Participants With Death From Any Cause399 of 9,333

506 of 9,291

-1.2 points

-1.8 to -0.6

18,624NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke901 of 9,333

1,065 of 9,291

-1.8 points

-2.7 to -0.9

18,624NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

MVA-BN-RSV vs Placebo: deaths from any cause41 of 9,389

34 of 9,191

0.1 points

-0.1 to 0.3

18,580NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: serious adverse events517 of 9,389

422 of 9,191

0.9 points

0.3 to 1.5

18,580NCT05238025

MVA-BN-RSV Vaccine Trial

TICAGRELOR vs CLOPIDOGREL: Participants With Any Major Bleeding Event961 of 9,235

929 of 9,186

0.3 points

-0.6 to 1.2

18,421NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

TICAGRELOR vs CLOPIDOGREL: Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding362 of 9,235

306 of 9,186

0.6 points

0.0 to 1.1

18,421NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

TICAGRELOR vs CLOPIDOGREL: Participants With Major or Minor Bleeding1,339 of 9,235

1,215 of 9,186

1.3 points

0.3 to 2.3

18,421NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

TICAGRELOR vs CLOPIDOGREL: Participants With Non-procedural Major Bleeding235 of 9,235

180 of 9,186

0.6 points

0.2 to 1.0

18,421NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

MVA-BN-RSV vs Placebo: Number of Participants With Serious Adverse Events517 of 9,389

422 of 8,959

0.8 points

0.2 to 1.4

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Occurrence of Severe PCR Confirmed RSV-associated LRTD0 of 9,160

2 of 9,188

-0.0 points

-0.1 to 0.0

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Number of Participants With Unsolicited Adverse Events607 of 9,389

581 of 8,959

-0.0 points

-0.7 to 0.7

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Occurrence of PCR Confirmed RSV-associated LRTD With at Least 3 Symptoms12 of 9,160

21 of 9,188

-0.1 points

-0.2 to 0.0

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Occurrence of Complications Related to PCR-confirmed RSV Disease0 of 9,160

1 of 9,188

-0.0 points

-0.1 to 0.0

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Number of Participants With Grade 3 or Higher Adverse Events11 of 9,389

2 of 8,959

0.1 points

0.0 to 0.2

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Occurrence of Hospitalization Due to Confirmed RSV Disease or Due to Any Complication Related to RSV-confirmed Respiratory Disease0 of 9,160

1 of 9,188

-0.0 points

-0.1 to 0.0

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Occurrence of PCR Confirmed RSV-associated ARD42 of 9,160

82 of 9,188

-0.4 points

-0.7 to -0.2

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

MVA-BN-RSV vs Placebo: Occurrence of PCR Confirmed RSV-associated LRTD With at Least 2 Symptoms25 of 9,160

61 of 9,188

-0.4 points

-0.6 to -0.2

18,348NCT05238025

MVA-BN-RSV Vaccine Trial

Clinical Decision Support (Cardiovascular Wizard) vs Usual Care: deaths from any cause207 of 10,775

159 of 7,454

-0.2 points

-0.6 to 0.2

18,229NCT02759055

Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)

Clinical Decision Support (Cardiovascular Wizard) vs Usual Care: serious adverse events1,836 of 10,775

1,360 of 7,454

-1.2 points

-2.3 to -0.1

18,229NCT02759055

Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=23

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00391872-3d94e6dd",
        "title": "TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke",
        "summary": "864 of 9333 against 1014 of 9291; risk difference -1.7 points, 95% interval -2.5 to -0.8; NCT00391872, A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT00391872-3d94e6dd",
        "nct_id": "NCT00391872",
        "kind": "outcome",
        "participants": 18624,
        "risk_difference": {
          "value": -0.016563140551297192,
          "lower": -0.02521936097207644,
          "upper": -0.007915809832015229
        },
        "group_1": "864 of 9,333",
        "group_2": "1,014 of 9,291",
        "difference": "-1.7 points",
        "interval": "-2.5 to -0.8",
        "trial_title": "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome"
      },
      {
        "id": "NCT00391872-51df9737",
        "title": "TICAGRELOR vs CLOPIDOGREL: Participants With Death From Any Cause",
        "summary": "399 of 9333 against 506 of 9291; risk difference -1.2 points, 95% interval -1.8 to -0.6; NCT00391872, A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT00391872-51df9737",
        "nct_id": "NCT00391872",
        "kind": "outcome",
        "participants": 18624,
        "risk_difference": {
          "value": -0.011709779800590923,
          "lower": -0.017907613325256852,
          "upper": -0.005536972646425837
        },
        "group_1": "399 of 9,333",
        "group_2": "506 of 9,291",
        "difference": "-1.2 points",
        "interval": "-1.8 to -0.6",
        "trial_title": "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=24",
  "request_id": "bLuRUrv4y55mmGk1"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?